SCHEMBL20074766

SCHEMBL20074766

CC(C)n1cncc1-c1cc(C(=O)NC(C)(C)C)cc(-c2ccc(F)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK2 P49760 2/20 0.41
CLK3 P49761 2/20 0.41
GSK3B P49841 2/20 0.41
DYRK1A Q13627 2/20 0.41
TNIK Q9UKE5 3/20 0.38
WNT1 P04628 1/20 0.38
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
SCN10A Q9Y5Y9 1/20 0.37
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
JAK2 O60674 1/20 0.36
TGFBR1 P36897 2/20 0.36
TGFBR2 P37173 2/20 0.36
CYP17A1 P05093 1/20 0.35
CYP3A4 P08684 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
P4HTM Q9NXG6 1/20 0.35
P2RY14 Q15391 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30089420 1.00 CLK2 (0.41) CLK2CLK3GSK3BDYRK1ATNIK
SCHEMBL20074802 0.90 P2RY14 (0.45) CLK2CLK3GSK3BDYRK1AMAPT
SCHEMBL20074710 0.89 GSK3B (0.43) CLK2CLK3GSK3BDYRK1ASCN10A
SCHEMBL20075391 0.86 GSK3B (0.51) CLK2CLK3GSK3BDYRK1AWNT1
SCHEMBL20075362 0.85 WNT1 (0.39) CLK2CLK3GSK3BDYRK1AWNT1
SCHEMBL20074610 0.84 HTR6 (0.42) CLK2CLK3GSK3BDYRK1AWNT1
SCHEMBL19641948 0.80 NR3C2 (0.42) LMNAMAPTTHRBSCN10AALOX5AP
SCHEMBL18706304 0.76 MAPT (0.39) LMNAMAPTTHRBSCN10AALOX5AP
SCHEMBL20074601 0.76 P2RY14 (0.48) MAPTALOX5APFEN1CYP3A4P2RY14
SCHEMBL20075350 0.75 P2RY14 (0.47) CLK2CLK3GSK3BDYRK1AWNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563049-B Imidazole compounds as EAAT3 inhibitors 豪夫迈·罗氏有限公司 2022-11-29 CN claimed
EP-3526201-B1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2020-11-18 EP claimed
CN-109563049-B Imidazole compounds as EAAT3 inhibitors 豪夫迈·罗氏有限公司 2022-11-29 CN disclosed
EP-3526201-B1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2020-11-18 EP disclosed
EP-3526201-B1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2020-11-18 EP disclosed
US-10556870-B2 Imidazole compounds as EAAT3 inhibitors HOFFMANN-LA ROCHE INC. (US) 2020-02-11 US disclosed
US-10556870-B2 Imidazole compounds as EAAT3 inhibitors HOFFMANN-LA ROCHE INC. (US) 2020-02-11 US disclosed
US-20190233379-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2019-08-01 US disclosed
US-20190233379-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2019-08-01 US disclosed
WO-2018069362-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10556870-B2 Imidazole compounds as EAAT3 inhibitors SLC1A1, SLC1A3, SLC1A2 CLK2 2424/4885CLK3 2582/4885GSK3B 2961/4885
US-20190233379-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS SLC1A1, SLC1A3, SLC1A2 CLK2 2424/4885CLK3 2582/4885GSK3B 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.